Skip to main content

Advertisement

Log in

Recommendations on the proper use of SGLT2 inhibitors

Diabetology International Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Author information

Authors and Affiliations

Consortia

Ethics declarations

Conflict of interest

Norio Abiru received honoraria from Novo Nordisk Pharma Ltd., and Astellas Pharma Inc. NA also received research funding from ONO Pharmaceutical Co., Ltd., Bristol-Myers Squibb, and Taisho Pharmaceutical Co., Ltd. Hiroshi Ikegami received honoraria from Astellas Pharma Inc., MSD K.K., Terumo Corporation, Eli Lilly Japan K.K., Novartis Pharma K.K. and Novo Nordisk Pharma Ltd. HI also received subsidies or donations from Taisho Toyama Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, Mitsubishi Tanabe Pharma Corporation, Novo Nordisk Pharma Ltd., ABBOTT JAPAN CO., LTD., Sumitomo Dainippon Pharma Co., Ltd., Johnson & Johnson K.K., Medical Company, Astellas Pharma Inc., ONO PHARMACEUTICAL CO., LTD., Kyowa Kirin Co., Ltd., DAIICHI SANKYO COMPANY, LIMITED, Nippon Boehringer Ingelheim Co., Ltd. and Bayer Yakuhin, Ltd. Nobuya Inagaki received honoraria from Kowa Pharmaceutical. NI also received research funding from AstraZeneca, Daiichi Sankyo and Mitsubishi Tanabe Pharma Corporation. NI also received subsidies or donations from Astellas Pharma Inc., MSD, Ono Pharmaceutical Co., Ltd., Sanwa Kagaku Kenkyusho Co. Ltd., Kissei Pharmaceutical, Kyowa Hakko Kirin, Sanofi, Daiichi Sankyo, Taisho Toyama Pharmaceutical Co. Ltd., Sumitomo Dainippon Pharma Inc., Takeda Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Teijin Pharma Ltd., Eli Lilly Japan, Japan Tobacco, Nippon Boehringer Ingelheim Co., Ltd., Novartis Pharma and Novo Nordisk Pharma Ltd. Kohjiro Ueki received honoraria from Novo Nordisk, Kyowa-Kirin, Takeda Pharmaceutical Co. Ltd., Astellas Pharma Inc., Mitsubishi Tanabe Pharma Corporation, AstraZeneca, MSD, Sanofi, Ono Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Inc. and Boehringer Ingelheim. KU also received research funding from Novo Nordisk, Eli Lilly, Boehringer Ingelheim, MSD, Abbott and Astellas Pharma Inc. KU also received subsidies or donations from Sanofi, Astellas Pharma Inc., Novo Nordisk, Eli Lilly, Takeda Pharmaceutical Co. Ltd., Kyowa-Kirin, Ono Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation and Sumitomo Dainippon Pharma Inc. Kohei Kaku is in the employment/leadership position/Advisory role for Sanwa Kagaku Kenkyusho Co. Ltd. KK also received honoraria from Astellas Pharma Inc., AstraZeneca, Daiichi-Sankyo, MSD, Ono Pharmaceutical Co., Ltd., Novo Nordisk Pharma Ltd., Boehringer Ingelheim Japan, Inc., Taisho Toyama Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Corporation and Kowa Pharmaceutical. KK also received subsidies or donations from Boehringer Ingelheim Japan, Inc., Taisho Toyama Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Corporation and Kowa Pharmaceutical. Takashi Kadowaki received honoraria from Abbott, Astellas Pharma Inc., AstraZeneca, Bayer, Boehringer Ingelheim, Cosmic, Daiichi Sankyo, Eli Lilly, FUJIFILM Corporation, Johnson & Johnson, Kissei Pharmaceutical, Kowa Pharmaceutical, Kyowa Hakko Kirin, Medical Review Co., Ltd., Medical View Co., Ltd., Medscape Education, Medtronic Sofamor Danek Co., Ltd., Mitsubishi Tanabe Pharma Corporation, MSD, Musashino Foods Corporation, Nipro Corporation, Novartis Pharma, Novo Nordisk Pharma Ltd., Ono Pharmaceutical Co., Ltd., Sanofi, Sanwa Kagaku Kenkyusho Co. Ltd., Sumitomo Dainippon Pharma Inc., Taisho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co. Ltd. and Terumo Corporation. TK also received research funding from AstraZeneca, Daiichi Sankyo and Takeda Pharmaceutical Co. Ltd. TK also received subsidies or donations from Astellas Pharma Inc., Daiichi Sankyo, Eli Lilly, Kissei Pharmaceutical, Mitsubishi Tanabe Pharma Corporation, MSD, Novo Nordisk Pharma Ltd., Ono Pharmaceutical Co., Ltd., Sanofi, Sumitomo Dainippon Pharma Inc., Taisho Pharmaceutical Co., Ltd. and Takeda Pharmaceutical Co. Ltd. TK also belongs to endowed departments by Asahi Mutual Life Insurance Company, Boehringer Ingelheim, Kowa Pharmaceutical, Mitsubishi Tanabe Pharma Corporation, MSD, Novo Nordisk Pharma Ltd., Ono Pharmaceutical Co., Ltd., and Takeda Pharmaceutical Co. Ltd. Yutaka Seino received honoraria from MSD, Kao, Taisho Pharmaceutical Co., Ltd., Taisho Toyama Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., Becton, Dickinson and Company, Boehringer Ingelheim and Novo Nordisk Pharma Ltd. Masakazu Haneda received honoraria from Astellas Pharma Inc., Taisho Toyama Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Boehringer Ingelheim, Taisho Pharmaceutical Co., Ltd., Kowa Pharmaceutical, Ono Pharmaceutical Co., Ltd., MSD, Novartis Pharma and Novo Nordisk. MH also received research funding from Novo Nordisk, Ono Pharmaceutical Co., Ltd., Shionogi & Co., Ltd. and Johnson & Johnson. Shinichi Sato declares that he has no conflict of interest.

Ethics policy

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is the English version of the “Recommendations on the Proper Use of SGLT2 Inhibitors” (http://www.fa.kyorin.co.jp/jds/uploads/recommendation_SGLT2.pdf) released in Japanese on August 6, 2019 on the official website of the Japan Diabetes Society, and has been jointly published in Journal of Diabetes Investigation (the official journal of the Asian Association for the Study of Diabetes: https://doi.org/10.1111/jdi.13160) and Diabetology International (the official English journal of JDS).

Appendix

Appendix

The members of the Committee on the Proper Use of SGLT2 Inhibitors: Norio Abiru (Department of Endocrinology and Metabolism, Nagasaki University Hospital), Hiroshi Ikegami (Department of Endocrinology, Metabolism and Diabetes, Faculty of Medicine, Kindai University), Nobuya Inagaki (Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine), Kohjiro Ueki (Diabetes Research Center, Research Institute, National Center for Global Health and Medicine), Kohei Kaku (Kawasaki Medical School/Kawasaki University of Medical Welfare), Takashi Kadowaki (Department of Prevention of Diabetes and Lifestyle-Related Diseases, Graduate School of Medicine, The University of Tokyo/Department of Metabolism and Nutrition, Mizonokuchi Hospital, Faculty of Medicine, Teikyo University), Shinichi Sato (Department of Dermatology, Graduate School of Medicine/Faculty of Medicine, University of Tokyo), Yutaka Seino (Kansai Electric Power Hospital), Masakazu Haneda (Division of Metabolism and Biosystemic Science, Department of Medicine, Asahikawa Medical University).

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

The Committee on the Proper Use of SGLT2 Inhibitors. Recommendations on the proper use of SGLT2 inhibitors. Diabetol Int 11, 1–5 (2020). https://doi.org/10.1007/s13340-019-00415-8

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13340-019-00415-8

Keywords

Navigation